These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 32061845)

  • 1. HER2 targeted biological macromolecule modified liposomes for improved efficacy of capecitabine in breast cancer.
    Singh MK; Pindiprolu SKSS; Sanapalli BKR; Yele V; Ganesh GNK
    Int J Biol Macromol; 2020 May; 150():631-636. PubMed ID: 32061845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor homing peptide modified liposomes of capecitabine for improved apoptotic activity and HER2 targeted therapy in breast cancer:
    Singh MK; Pindiprolu SKSS; Reddy Sanapalli BK; Yele V; Ganesh GNK
    RSC Adv; 2019 Aug; 9(43):24987-24994. PubMed ID: 35528678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity.
    Shahin M; Soudy R; Aliabadi HM; Kneteman N; Kaur K; Lavasanifar A
    Biomaterials; 2013 May; 34(16):4089-4097. PubMed ID: 23465829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and development of PEGylated liposomal formulation of HER2 blocker Lapatinib for enhanced anticancer activity and diminished cardiotoxicity.
    Shrivastava R; Trivedi S; Singh PK; Asif M; Chourasia MK; Khanna A; Bhadauria S
    Biochem Biophys Res Commun; 2018 Sep; 503(2):677-683. PubMed ID: 29908185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capecitabine-loaded nanoniosomes and evaluation of anticancer efficacy.
    Nazari-Vanani R; Karimian K; Azarpira N; Heli H
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):420-426. PubMed ID: 30672343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of synthetic peptide-modified liposomes with LDL receptor targeting capacity and improved anticancer activity.
    Liu M; Li W; Larregieu CA; Cheng M; Yan B; Chu T; Li H; Mao SJ
    Mol Pharm; 2014 Jul; 11(7):2305-12. PubMed ID: 24830852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
    Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
    Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer.
    Laginha KM; Moase EH; Yu N; Huang A; Allen TM
    J Drug Target; 2008 Aug; 16(7):605-10. PubMed ID: 18686132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved therapeutic activity of HER2 Affibody-targeted cisplatin liposomes in HER2-expressing breast tumor models.
    Alavizadeh SH; Akhtari J; Badiee A; Golmohammadzadeh S; Jaafari MR
    Expert Opin Drug Deliv; 2016; 13(3):325-36. PubMed ID: 26578208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis.
    Sun Z; Lan X; Xu S; Li S; Xi Y
    BMC Cancer; 2020 Mar; 20(1):180. PubMed ID: 32131770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
    Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
    Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy.
    Eloy JO; Petrilli R; Chesca DL; Saggioro FP; Lee RJ; Marchetti JM
    Eur J Pharm Biopharm; 2017 Jun; 115():159-167. PubMed ID: 28257810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2-positive breast cancer: Current and new therapeutic strategies.
    Escrivá-de-Romaní S; Arumí M; Bellet M; Saura C
    Breast; 2018 Jun; 39():80-88. PubMed ID: 29631097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel anti-HER2 peptide-conjugated theranostic nanoliposomes combining NaYF
    Panikar SS; Ramírez-García G; Vallejo-Cardona AA; Banu N; Patrón-Soberano OA; Cialla-May D; Camacho-Villegas TA; de la Rosa E
    Nanoscale; 2019 Nov; 11(43):20598-20613. PubMed ID: 31641713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P435 HER2/neu-derived peptide conjugated to liposomes containing DOPE as an effective prophylactic vaccine formulation for breast cancer.
    Farzad N; Barati N; Momtazi-Borojeni AA; Yazdani M; Arab A; Razazan A; Shariat S; Mansourian M; Abbasi A; Saberi Z; Badiee A; Jalali SA; Jaafari MR
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):665-673. PubMed ID: 30829072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective suppression of tumour cells by oligoclonal HER2-targeted delivery of liposomal doxorubicin.
    Farasat A; Rahbarizadeh F; Ahmadvand D; Ranjbar S; Khoshtinat Nikkhoi S
    J Liposome Res; 2019 Mar; 29(1):53-65. PubMed ID: 29621912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapamycin-loaded Immunoliposomes Functionalized with Trastuzumab: A Strategy to Enhance Cytotoxicity to HER2-positive Breast Cancer Cells.
    Eloy JO; Petrilli R; Brueggemeier RW; Marchetti JM; Lee RJ
    Anticancer Agents Med Chem; 2017; 17(1):48-56. PubMed ID: 27225450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial.
    Welt A; Marschner N; Lerchenmueller C; Decker T; Steffens CC; Koehler A; Depenbusch R; Busies S; Hegewisch-Becker S
    Breast Cancer Res Treat; 2016 Feb; 156(1):97-107. PubMed ID: 26927446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and Evaluation of Tri-Functional Immunoliposomes for the Treatment of HER2 Positive Breast Cancer.
    Vaidya T; Straubinger RM; Ait-Oudhia S
    Pharm Res; 2018 Mar; 35(5):95. PubMed ID: 29536232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced drug internalization and therapeutic efficacy of PEGylated nanoparticles by one-step formulation with anti-mPEG bispecific antibody in intrinsic drug-resistant breast cancer.
    Cheng YA; Chen IJ; Su YC; Cheng KW; Lu YC; Lin WW; Hsieh YC; Kao CH; Chen FM; Roffler SR; Cheng TL
    Biomater Sci; 2019 Aug; 7(8):3404-3417. PubMed ID: 31251311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.